scholarly journals Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors

2019 ◽  
Vol 10 (7) ◽  
Author(s):  
Jordan Gabrielsen, PharmD ◽  
Gianna Girone, PharmD ◽  
Bonita Bennett, BSN ◽  
Anna Jung, PharmD, BCPS
Keyword(s):  
Neuroendocrine Tumors ◽  
Safety Monitoring ◽  
Somatostatin Analogue ◽  
Monitoring Protocol ◽  
Long Acting

Treatment of gastro-entero-pancreatic (GEP) neuroendocrine tumors with lanreotide, a new-long-acting somatostatin analogue

1998 ◽  
Vol 114 ◽  
pp. A643
Author(s):  
M. Migliori ◽  
P. Tomassetti ◽  
GC Montini ◽  
S Lalli ◽  
R. Corinaldesi
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analogue ◽  
Long Acting

INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE

2018 ◽  
Vol 24 (2) ◽  
pp. 189-194
Author(s):  
Michael Tadman ◽  
Philip Charlton ◽  
Bahram Jafar-Mohammadi ◽  
Denis Talbot ◽  
Ashley B. Grossman
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analogue ◽  
Single Center ◽  
Long Acting

scholarly journals Successful treatment with a long-acting somatostatin analogue(SMS201-995) in a patient with malignant carcinoid syndrome.

1988 ◽  
Vol 27 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Masayuki TSUDA ◽  
Shigehisa TAMAKI ◽  
Eiichi IWASAKI ◽  
Seikou MURASHIMA ◽  
Katsumi DEGUCHI ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Carcinoid Syndrome ◽  
Somatostatin Analogue ◽  
Malignant Carcinoid ◽  
Malignant Carcinoid Syndrome ◽  
Long Acting

Effective Therapy of Insulinoma by Using Long-Acting Somatostatin Analogue. A Case Report and Literature Review

2011 ◽  
Vol 120 (02) ◽  
pp. 68-72 ◽  
Author(s):  
A. Jawiarczyk ◽  
M. Bolanowski ◽  
J. Syrycka ◽  
G. Bednarek-Tupikowska ◽  
M. Kałużny ◽  
...  
Keyword(s):  
Adrenal Gland ◽  
Somatostatin Receptors ◽  
Subcutaneous Administration ◽  
Pancreatic Neuroendocrine Tumor ◽  
Somatostatin Analogue ◽  
Left Adrenal Gland ◽  
Glucose Levels ◽  
Long Acting ◽  
The Right

AbstractWe are reporting a case of 68-year-old woman with insulinoma, after a non-successful tumor surgery and a long-term diazoxide treatment. She had a lot of hypoglycemia cases, and a weight gain of 50 kg. An abdominal CT scan demonstrated a tumor 28 mm in the diameter, in the head of the pancreas. The patient did not agree for the repeated insulinoma surgery. Furthermore, we found a lesion in the left adrenal gland (14 mm in the diameter) and in the right lung (8 mm in the diameter). Pheochromocytoma was diagnosed on the basis of hypertension, elevated levels of normetanephrine in the 24-h urine collection, and an elevated level of norepinephrine in a plasma sample. After the left adrenal gland removal we observed lower blood pressure. Since we had revealed the presence of somatostatin receptors by the somatostatin receptors scintigraphy, we decided to control hypoglycemia by a monthly subcutaneous administration of the long-acting lanreotide. Because of higher glucose levels (300–400 mg/dl) we started an intense insulin therapy. Nowadays, the patient feels better, she has lost 20 kg of her body weight, and we have observed normal blood glucose levels during the long-term lanreotide treatment. We have noticed neither side effects nor hypoglycemic episodes and we have reduced the dose of insulin. The presented case can be an evidence of the effective treatment of the pancreatic neuroendocrine tumor of insulinoma type, with somatostatin analogue.

Effect of Octreotide, a Long-Acting Somatostatin Analogue, on Plasma Amino Acid Uptake by the Pancreas

Pancreas ◽  
1991 ◽  
Vol 6 (6) ◽  
pp. 668-672 ◽  
Author(s):  
L. Gullo ◽  
R. Pezzilli ◽  
Dvora Ancona ◽  
A. Morselli Labate ◽  
L. Barbara
Keyword(s):  
Amino Acid ◽  
Amino Acid Uptake ◽  
Plasma Amino Acid ◽  
Somatostatin Analogue ◽  
Acid Uptake ◽  
Long Acting

scholarly journals 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

2021 ◽  
pp. 1167-1175
Author(s):  
Swayamjeet Satapathy ◽  
Bhagwant R. Mittal ◽  
Ashwani Sood ◽  
Apurva Sood ◽  
Rakesh Kapoor ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Systemic Therapy ◽  
Objective Response ◽  
Progression Free Survival ◽  
First Line ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Free Survival ◽  
Octreotide Lar ◽  
Treatment Naïve ◽  
Long Acting

PURPOSE To compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). MATERIALS AND METHODS Data of consecutive patients of advanced inoperable or metastatic grade 1 or 2 GEP-NETs treated with first-line 177Lu-DOTATATE plus radiosensitizing capecitabine or octreotide LAR from September 2012 to December 2019 were collected and analyzed for response, toxicity, and survival outcomes. RESULTS Seventy-six patients (median age: 53 years; range 14-81 years) with treatment-naïve advanced grade 1 or 2 GEP-NETs were included. Thirty-six patients received a median cumulative dose of 27.3 GBq of 177Lu-DOTATATE intravenously at 8-12 weeks' intervals along with 1,250 mg/m2 oral capecitabine on days 0-14 of each cycle of 177Lu-DOTATATE, whereas 40 patients were administered 30 mg octreotide LAR intramuscularly every 4 weeks. Using response evaluation criteria in solid tumor 1.1, the objective response rate was 38% in the 177Lu-DOTATATE arm compared with 15% in the octreotide LAR arm ( P = .025), whereas the disease control rates were 88% and 67% in 177Lu-DOTATATE and octreotide LAR arms, respectively ( P = .035). The median durations of progression-free survival in the 177Lu-DOTATATE and octreotide LAR arms were 54 months and 16 months, respectively ( P = .017), whereas the median overall survival was not reached and not significantly different across both the arms. Of the treatment-related adverse events, no major difference was observed in the occurrence of grade 3 or 4 toxicities between the two treatment arms. CONCLUSION First-line systemic 177Lu-DOTATATE plus radiosensitizing capecitabine achieved better radiologic response and longer progression-free survival compared with octreotide LAR in patients with advanced grade 1 or 2 GEP-NETs. Future randomized controlled trials are, however, required to determine the best treatment sequence for the treatment-naïve patients with advanced GEP-NETs.

Hepatic cytoreduction followed by a novel long-acting somatostatin analog: A paradigm for intractable neuroendocrine tumors metastatic to the liver

Surgery ◽  
2001 ◽  
Vol 130 (6) ◽  
pp. 954-962 ◽  
Author(s):  
Mathew H. Chung ◽  
Joseph Pisegna ◽  
Mitchell Spirt ◽  
Armando E. Giuliano ◽  
Wei Ye ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Analog ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document